Exagen Operating Cycle from 2010 to 2026
| XGN Stock | USD 3.51 0.15 4.46% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 46.26 | Current Value 41.57 | Quarterly Volatility 26.45797089 |
Check Exagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exagen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 2.8 M or Selling General Administrative of 29.1 M, as well as many indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0169 or PTB Ratio of 7.39. Exagen financial statements analysis is a perfect complement when working with Exagen Valuation or Volatility modules.
Exagen | Operating Cycle | Build AI portfolio with Exagen Stock |
Evaluating Exagen's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Exagen Inc's fundamental strength.
Latest Exagen's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Exagen Inc over the last few years. It is Exagen's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exagen's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Exagen Operating Cycle Regression Statistics
| Arithmetic Mean | 37.74 | |
| Geometric Mean | 27.23 | |
| Coefficient Of Variation | 70.10 | |
| Mean Deviation | 22.01 | |
| Median | 41.57 | |
| Standard Deviation | 26.46 | |
| Sample Variance | 700.02 | |
| Range | 84.7733 | |
| R-Value | 0.67 | |
| Mean Square Error | 416.27 | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 3.49 | |
| Total Sum of Squares | 11,200 |
Exagen Operating Cycle History
About Exagen Financial Statements
Exagen investors utilize fundamental indicators, such as Operating Cycle, to predict how Exagen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 46.26 | 41.57 |
Pair Trading with Exagen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.Moving together with Exagen Stock
Moving against Exagen Stock
| 0.87 | DSGN | Design Therapeutics | PairCorr |
| 0.8 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.78 | ENGN | enGene Holdings Common | PairCorr |
| 0.56 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.52 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Exagen Correlation against competitors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Exagen diversify its offerings? Factors like these will boost the valuation of Exagen. Anticipated expansion of Exagen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Exagen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.90) | Revenue Per Share | Quarterly Revenue Growth 0.379 | Return On Assets | Return On Equity |
Investors evaluate Exagen Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exagen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Exagen's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Exagen's market price signifies the transaction level at which participants voluntarily complete trades.